Kindred Biosciences, Inc.

Kindred Biosciences, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Kindred Biosciences, Inc. is not a good value stock. Kindred Biosciences, Inc. is a mediocre stock to choose.

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving...

News

Kingstone Companies Restructures Debt and Extends Warrants

TipRanks Financial Blog Kingstone Companies (KINS) just unveiled an update. Kingstone Companies, Inc. has struck a deal with its noteholders to exchange $19.95 million worth of existing hi...\n more…

Kingstone Companies Announces Executive Chair Transition and Bylaw Amendments

TipRanks Financial Blog Kingstone Companies (KINS) has provided an announcement. Mr. Goldstein is set to retire as Executive Chairman of the Board on September 10, 2024, with Mr. Newgarden...\n more…

Kingstone Companies chairman Barry Goldstein to retire

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Kingstone Companies, Inc.'s (NASDAQ:KINS) market cap touched US$112m last week, benefiting both retail investors who own 59% as well as institutions

Simply Wall St Key Insights Significant control over Kingstone Companies by retail investors implies that the general public has more...\n more…

Kingstone Companies, Inc. 2024 Q2 - Results - Earnings Call Presentation

SeekingAlpha Kingstone Companies, Inc. 2024 Q2 - Results - Earnings Call Presentation...\n more…

Kingstone Companies, Inc. (KINS) Q2 2024 Earnings Call Transcript

SeekingAlpha Kingstone Companies, Inc. (KINS) Q2 2024 Earnings Call Transcript...\n more…